ArticleNeurology(R) neuroimmunology & neuroinflammation2022
Innate Immune Cell-Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer's disease and multiple sclerosis: a systematic review.Frontiers in immunology · 2023Pooled it
- The effect of ibudilast on thalamic volume in progressive multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Trial
- The test-retest reproducibility of [EJNMMI research · 2026Article
- Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study.Journal of neurology · 2026Article
- The Relationship Between Inflammation and Central Nervous System in Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Decoding Thalamic Glial Interplay in Multiple Sclerosis Through Proton Magnetic Resonance Spectroscopy and Positron Emission Tomography.International journal of molecular sciences · 2025Article
- Longitudinal accumulation of glial activation measured by TSPO-PET predicts later brain atrophy in multiple sclerosis.Journal of neuroinflammation · 2025Article
- Predictors of risk of secondary progression in multiple sclerosis.Therapeutic advances in neurological disorders · 2025Article
- Microglia positron emission tomography and progression in multiple sclerosis: thalamus on fire.Brain communications · 2025Article
- The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors.Frontiers in immunology · 2025Review
- Serum glial fibrillary acid protein associates with TSPO-expressing lesions in multiple sclerosis brain.Therapeutic advances in neurological disorders · 2025Article
- P2XEJNMMI research · 2024Article
- Article
- Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals.Frontiers in neurology · 2024Article
- Article
- PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.Journal of neurology · 2023Article
- Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation.Frontiers in neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesOur aim was to investigate whether 18-kDa translocator protein (TSPO) radioligand binding in gray matter (GM) predicts later disability progression in multiple sclerosis (MS).
methodsIn this prospective imaging study, innate immune cells were investigated in the MS patient brain using PET imaging. The distribution volume ratio (DVR) of the TSPO-binding radioligand [
resultsThe cohort consisted of 66 patients with MS and 18 healthy controls. Patients with later disability progression (n = 17) had more advanced atrophy in the thalamus, caudate, and putamen at baseline compared with patients with no subsequent worsening. TSPO binding was significantly higher in the thalamus among the patients with later worsening. The thalamic DVR was the only measured imaging variable that remained a significant predictor of disability progression in the regression model. The final model predicted disability progression with 52.9% sensitivity and 93.9% specificity with an area under the curve value of 0.82 (receiver operating characteristic curve). DISCUSSION: Increased TSPO radioligand binding in the thalamus has potential in predicting short-term disability progression in MS and seems to be more sensitive for this than GM atrophy measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.